Ginkgo Bioworks/$DNA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ginkgo Bioworks
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
- Ticker
- $DNA
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 485
- Headquarters
- Boston, United States
- Website
- www.ginkgo.bio
Ginkgo Bioworks Metrics
BasicAdvanced
$674M
-
-$4.96
1.79
-
Price and volume
Market cap
$674M
Beta
1.79
52-week high
$18.22
52-week low
$5.37
Average daily volume
3.1M
Financial strength
Current ratio
4.572
Quick ratio
4.333
Long term debt to equity
0.962
Total debt to equity
0.962
Profitability
EBITDA (TTM)
-271.598
Gross margin (TTM)
68.04%
Net profit margin (TTM)
-219.60%
Operating margin (TTM)
-231.78%
Effective tax rate (TTM)
0.19%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-17.27%
Return on equity (TTM)
-59.94%
Valuation
Price to revenue (TTM)
4.43
Price to book
1.52
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
-3.356
Free cash flow yield (TTM)
-29.80%
Free cash flow per share (TTM)
-2.983
Growth
Revenue change (TTM)
-37.02%
Earnings per share change (TTM)
-15.30%
3-year revenue growth (CAGR)
-25.94%
3-year earnings per share growth (CAGR)
-43.08%
Bulls say / Bears say
Ginkgo has begun work on a 97-instrument autonomous lab for Pacific Northwest National Laboratory and has further deployments at Caltech, Northwestern and Maryland. These projects provide tangible demand for its automation platform as Nebula scales. (Ginkgo Bioworks)
An ARPA-H programme awarded Ginkgo a subcontract worth up to $17.5 million to help develop compact manufacturing for personalised RNA medicines. This adds a funded government opportunity beyond its lab-network projects, although Ginkgo is a subcontractor, not the prime contractor. (Investing News Network)
ADME-One reportedly attracted 17 customers within six weeks of launch and is priced at $199 per panel, well below typical CRO quotes. That is an early sign the service could broaden Ginkgo’s commercial reach, but it does not yet prove repeat or material revenue. (Kalkine)
Second-quarter revenue fell 48% to $20 million, with filings citing reduced scope from a large agriculture customer and fewer pharmaceutical and biotechnology projects. Shrinking legacy work is not yet being replaced by enough new platform sales. (StockTitan)
Cash economics remain weak: the second-quarter adjusted EBITDA loss widened to $36 million from $25 million, and quarterly cash burn was $45 million. Management still expects $125 million to $150 million of cash burn in 2026, which will keep reducing liquidity. (Ginkgo Bioworks)
Unused leased space cost $14 million in the second quarter, up from $12 million a year earlier, despite generating no current revenue. Subleasing could offset some of this burden, but the company has not yet removed the cost. (EarningsCalls.dev)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
Ginkgo Bioworks Financial Performance
Revenues and expenses
Ginkgo Bioworks Earnings Performance
Company profitability
Upcoming events
No upcoming events
Ginkgo Bioworks News
AllArticlesVideos
What's Going on With Ginkgo Bioworks Stock on Friday?
Benzinga2 weeks ago
Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
Business Wire2 weeks ago
Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
Business Wire1 month ago
Funds containing Ginkgo Bioworks
Fund name | Fund size | $DNA weighting |
|---|---|---|
L&G Artificial Intelligence£AIAG | $2.1B | 0.88% |
L&G Artificial Intelligence$AIAI | $2.1B | 0.88% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.